This is really a fascinating and exciting talk, by Michael A. Weiss, MD, PhD, MBA, a professor at Indiana University School of Medicine and co-founder of Thermalin Inc., a privately held biotechnology company.
In February 2020, JDRF International presented Dr. Weiss with the prestigious Gerold and Kayla Grodsky Basic Research Scientist Award, for his work on insulin structure and signaling with application to therapeutic insulin analog design. His laboratory has synthesized numerous insulin analogs and contributed immensely to the world’s understanding of the structures of insulin, pro-insulin, rapid-acting analogs, and basal analogs and of the mechanics of the hormone’s binding to the insulin receptor.
In 2010, Dr. Weiss founded Thermalin Diabetes, LLC, which sought to design novel ultra-stable pump-based insulin analogs, and he currently serves as Chief Innovation Officer of its successor entity, Thermalin Inc. Dr. Weiss is Chair of the Department of Biochemistry & Molecular Biology and a member of the Center for Diabetes and Metabolic Diseases at the Indiana University School of Medicine. He is also a member of the Department of Chemistry at Indiana University in Bloomington and the Department of Biomedical Engineering at Purdue University.
An awesome quote from Dr. Weiss: “My hope, against my self-interest, is that fewer and fewer people will eventually need insulin. But in the meantime, we’ll be making sure that people who have diabetes remain healthy and without such dreaded long-term complications as renal failure, amputations or blindness.”